Dr. Naylor’s clinical and research expertise are in genetic and atypical forms of diabetes. She is a co-Investigator of the US National Monogenic Diabetes Registry housed at the University of Chicago, an investigator of the rare and atypical diabetes network, or RADIANT study and contributes to the American Diabetes Association Precision Medicine in Diabetes Initiative. Her work addresses barriers to accurate genetic diagnosis of MODY and inequities in who benefits from diabetes precision medicine. She has carried out cost-effectiveness analyses demonstrating the economic value of accurate genetic diagnosis of MODY and ongoing studies seek to clarify best management practices for MODY and support broader implementation of precision medicine in diabetes.
The Do-It-Yourself Artificial Pancreas.
Palmer W, Greeley SAW, Naylor R. The Do-It-Yourself Artificial Pancreas. Pediatr Ann. 2021 Jul; 50(7):e304-e307.
PMID: 34264792
Using a Do-It-Yourself Artificial Pancreas: Perspectives from Patients and Diabetes Providers.
Palmer W, Greeley SAW, Letourneau-Freiberg LR, Naylor RN. Using a Do-It-Yourself Artificial Pancreas: Perspectives from Patients and Diabetes Providers. J Diabetes Sci Technol. 2020 09; 14(5):860-867.
PMID: 32680447
The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing.
GoodSmith MS, Skandari MR, Huang ES, Naylor RN. The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing. Diabetes Care. 2019 12; 42(12):2247-2255.
PMID: 31558549
Pediatric Monogenic Diabetes: A Unique Challenge and Opportunity.
Harris A, Naylor RN. Pediatric Monogenic Diabetes: A Unique Challenge and Opportunity. Pediatr Ann. 2019 Aug 01; 48(8):e319-e325.
PMID: 31426100
Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2).
Gregory JM, Smith TJ, Slaughter JC, Mason HR, Hughey CC, Smith MS, Kandasamy B, Greeley SAW, Philipson LH, Naylor RN, Letourneau LR, Abumrad NN, Cherrington AD, Moore DJ. Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2). Diabetes. 2019 08; 68(8):1565-1576.
PMID: 31092478
GCK-MODY in the US Monogenic Diabetes Registry: Description of 27 unpublished variants.
Sanyoura M, Letourneau L, Knight Johnson AE, Del Gaudio D, Greeley SAW, Philipson LH, Naylor RN. GCK-MODY in the US Monogenic Diabetes Registry: Description of 27 unpublished variants. Diabetes Res Clin Pract. 2019 May; 151:231-236.
PMID: 31063852
Economics of Genetic Testing for Diabetes.
Naylor R. Economics of Genetic Testing for Diabetes. Curr Diab Rep. 2019 03 27; 19(5):23.
PMID: 30919097
Management and pregnancy outcomes of women with GCK-MODY enrolled in the US Monogenic Diabetes Registry.
Dickens LT, Letourneau LR, Sanyoura M, Greeley SAW, Philipson LH, Naylor RN. Management and pregnancy outcomes of women with GCK-MODY enrolled in the US Monogenic Diabetes Registry. Acta Diabetol. 2019 Apr; 56(4):405-411.
PMID: 30535721
Monogenic Diabetes in Children and Adolescents: Recognition and Treatment Options.
Sanyoura M, Philipson LH, Naylor R. Monogenic Diabetes in Children and Adolescents: Recognition and Treatment Options. Curr Diab Rep. 2018 06 22; 18(8):58.
PMID: 29931562
Clinical Management of Women with Monogenic Diabetes During Pregnancy.
Dickens LT, Naylor RN. Clinical Management of Women with Monogenic Diabetes During Pregnancy. Curr Diab Rep. 2018 02 15; 18(3):12.
PMID: 29450745